个人简介：

Former Senior Director, Johnson & Johnson Global External innovation, the pioneer to setup J&J Innovation Asia-Pacific & Jlabs Shanghai and lead over 50 external collaborationprojects, a seasoned leader in drug discovery & development, company incubation andbusiness development with strong education and research background in Yale Univ.Harvard Univ.and China Phammaceutical Uniy.

Director and former President of Sino-American Pharmaceutical Professionals Association(SAPA), helped establish Marketing Authorization Holder (MAH) policy in China fromindustry perspective.

公司简介：

Innolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases to improve life of patients around the world. Innolake was co-founded by two industry veterans, Dr. Mingde Xia (former Sr. Director of Global External Innovation at Johnson & Johnson) and Mr. Robert Chen (former founding member and Executive Vice President of Genor Biopharma, one of pioneering therapeutic antibody companies in China) in 2020. The company debuted with a top-tier and enthusiastic scientific & clinical development team and $40 million Series Pre-A. By continuously building proprietary technology platforms and R&D capabilities, Innolake places innovation at the cornerstone of its overall strategy. Through in-house R&D and partnering with global MNCs and biotech companies, Innolake has established a robust pipeline with more than ten first-in-class and best-in-class drug candidates, two of which have entered the clinical stage. Recently, Innolake was recognized as a “Chinese Next Unicorn” enterprise and listed on ”2021 China Biopharmaceutical Industry Innovation Top100 List”.